key: cord-0747189-5j8de4hw
authors: Wander, Pandora L.; Lowy, Elliott; Beste, Lauren A.; Tulloch-Palomino, Luis; Korpak, Anna; Peterson, Alexander C.; Kahn, Steven E.; Boyko, Edward J.
title: The Incidence of Diabetes Among 2,777,768 Veterans With and Without Recent SARS-CoV-2 Infection
date: 2022-02-27
journal: Diabetes Care
DOI: 10.2337/dc21-1686
sha: 8d02f1bce883e51835389fd96ded808f0b913ad7
doc_id: 747189
cord_uid: 5j8de4hw

OBJECTIVE: To examine associations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection/coronavirus disease 2019 with incident diabetes. RESEARCH DESIGN AND METHODS: We conducted a retrospective cohort study using Veterans Health Administration data. We defined all patients without preexisting diabetes with one or more nasal swabs positive for SARS-CoV-2 (1 March 2020–10 March 2021; n = 126,710) as exposed and those with no positive swab and one or more laboratory tests (1 March 2020–31 March 2021; n = 2,651,058) as unexposed. The index date for patients exposed was the date of first positive swab and for patients unexposed a random date during the month of the qualifying laboratory test. We fit sex-stratified logistic regression models examining associations of SARS-CoV-2 with incident diabetes within 120 days and all follow-up time through 1 June 2021. A subgroup analysis was performed among hospitalized subjects only to help equalize laboratory surveillance. RESULTS: SARS-CoV-2 was associated with higher risk of incident diabetes, compared with no positive tests, among men (120 days, odds ratio [OR] 2.56 [95% CI 2.32–2.83]; all time, 1.95 [1.80–2.12]) but not women (120 days, 1.21 [0.88–1.68]; all time, 1.04 [0.82–1.31]). Among hospitalized participants, SARS-CoV-2 was associated with higher risk of diabetes at 120 days and at the end of follow-up in men (OR 1.42 [95% CI 1.22–1.65] and 1.32 [1.16–1.50], respectively) but not women (0.72 [0.34–1.52] and 0.80 [0.44–1.45]). Sex ∗ SARS-CoV-2 interaction P values were all <0.1. CONCLUSIONS: SARS-CoV-2 is associated with higher risk of incident diabetes in men but not in women even after greater surveillance related to hospitalization is accounted for.

beyond the acute postviral recovery period (5) (6) (7) and appear to involve both pulmonary and extrapulmonary complications, including metabolic diseases. Thus, the COVID-19 pandemic may contribute to a higher diabetes incidence wherever SARS-CoV-2 infection has affected a substantial proportion of the population.

A link between SARS-CoV-2/COVID-19 infection and new-onset diabetes has been postulated (8) . Previous reports have estimated the magnitude of the association of SARS-CoV-2 with newonset diabetes as one of many outcomes (5) (6) (7) . However, these previous reports may have underestimated the risk of incident diabetes after COVID-19 by defining new-onset diabetes based only on diagnostic codes, potentially missing cases by not examining pharmacy records for glucose-lowering medications or laboratory findings for glucose or hemoglobin A 1c (A1C) values. Estimates of the magnitude of the association in these reports may, therefore, be biased by misclassification of diabetes at baseline or follow-up or by surveillance bias due to increased frequency of laboratory testing among individuals diagnosed with and treated for COVID-19 compared with individuals not diagnosed with COVID-19. We sought to extend previous reports by 1) systematically excluding individuals with preexisting diabetes, 2) defining diabetes based on not only diagnostic codes but also laboratory measurements of glucose and A1C and use of glucose-lowering medications, and 3) using sample restriction to evaluate for the presence of surveillance bias.

In this analysis we used data from the Corporate Data Warehouse (CDW), a data repository derived from the electronic medical record of the Veterans Health Administration (VHA), the largest integrated health care system in the U.S. (9) . VA (Veterans Affairs) Informatics and Computing Infrastructure (VINCI) has extracted CDW data to create the COVID-19 Shared Data Resource containing analytic variables for all patients tested for SARS-CoV-2, which we accessed for this research (10). We defined all patients with one or more nasal swabs positive for SARS-CoV-2 between 1 March 2020 and 10 March 2021 as exposed. Most tests were performed in VA laboratories using U.S. Food and Drug Administrationapproved RealTime SARS-CoV-2 Assay (Abbott Laboratories) or Xpert Xpress SARS-CoV-2 assay (Cepheid). A small number was sent to outside laboratories. All laboratories were required to conform to standards for laboratory reporting set out in a VHA operational memo (11 February 2020) from the Deputy Under Secretary for Health for Operations and Management. Only tests performed by the Public Health Reference Laboratory of the VA Palo Alto Health Care System or by state and local health departments were allowed. Veterans receiving VHA care (i.e., with any inpatient or outpatient clinical encounter between 1 June 2019 and 30 May 2021) without a positive nasal swab for SARS-CoV-2 and with any laboratory test performed between 1 March 2020 and 31 March 2021 were chosen as the unexposed comparison group. For SARS-CoV-2-positive individuals, the index date was defined as the date the first positive test result was returned. For individuals without a positive test for SARS-CoV-2, the index date was defined as a random date during a month in which they had any laboratory test performed.

Individuals were excluded if they 1) had one or more abnormal laboratory values from plasma or serum (random glucose $200 mg/dL, fasting glucose $126 mg/dL, 2-h glucose from an oral glucose tolerance test $200 mg/dL) or whole blood (A1C $6.5%); 2) had any single ICD-9, Clinical Modification (ICD-9-CM), or ICD-10, Clinical Modification (ICD-10-CM), codes of 250 or E08-E13; or 3) received any glucose-lowering medication after 1 January 2000. Further, all participants were required to have at least one laboratory value that did not support a diagnosis of diabetes (random glucose #199 mg/dL, fasting glucose #125 mg/dL, 2-h glucose #199 mg/dL, or A1C #6.4%) measured during the same time period. Among VHA patients screened for eligibility in the current analysis, the proportion of SARS-CoV-2-positive individuals with preexisting diabetes was 45.2% (n 5 104,309). The proportion of individuals without a positive test with preexisting diabetes was 42.0% (n 5 1,917,638). The final sample size was n 5 126,710 diagnosed with COVID-19 and n 5 2,651,058 with no known COVID-19 diagnosis. To address the possibility that individuals diagnosed with COVID-19 might receive closer surveillance after COVID-19 diagnosis, we also identified a subgroup restricted to participants who were hospitalized in the 30 days after the index date: n 5 12,418 positive for SARS-CoV-2 and n 5 43,323 with no positive swabs for SARS-CoV-2. The study was approved by the institutional review board at VA Puget Sound Health Care System with the requirement for informed consent waived.

We collected data on age, sex, race/ethnicity, and facility location. BMI was defined as weight in kilograms divided by the square of height in meters. Veterans chose any number of race/ethnicity responses, which were categorized as selected/not selected for each individual response (e.g., White yes/no).

Smoking status was classified as current, former, or never based on self-report in VHA's national health factors database. If no smoking code was entered, the participant was classified as never smoked. We classified facility location using Veterans Integrated Service Networks, which comprise 18 regional systems of care within VHA. Participants were followed through 1 June 2021 for the development of diabetes defined as 1) two or more abnormal laboratory values from plasma or serum (random glucose $200 mg/dL, fasting glucose $126 mg/dL, 2-h glucose from an oral glucose tolerance test $200 mg/dL) or whole blood (A1C $6.5%) (11); 2) two outpatient or one inpatient ICD-10 codes of E08-E13; or 3) receipt of an initial and one refill prescription of a glucose-lowering medication. To avoid capturing transient hyperglycemia related to treatment with systemic corticosteroids, we excluded plasma glucose values collected within 30 days of the index date for all participants. We included diagnostic codes E08 (diabetes due to underlying condition) and E09 (drug-or chemicalinduced diabetes mellitus) because we did not want to miss any incident cases of diabetes that were miscoded. We did not include E14 (unspecified diabetes) because it is not used in the CDW to code diabetes. For the full cohort, incident diabetes was defined as diabetes that occurred 1) up to 120 days after the index date or 2) between the index date and 1 June 2021. For hospitalized participants, incident diabetes was defined as diabetes that occurred 1) between the date of admission and 120 days after the index date or 2) between the admission date and 1 June 2021.

We used DAGitty (12) for generation of a directed acyclic graph (DAG) to assist in model selection for confounder adjustment. We adjusted for variables thought to be causally associated with both likelihood of testing positive for SARS-CoV-2 and diagnosis of diabetes based on our DAG. By using these criteria, we determined that certain variables (e.g., COVID-19 treatments) would not be confounders. We examined for the presence of multiplicative first-order interactions of sex at birth with SARS-CoV-2 infection in models including all participants and fit sex-stratified logistic regression models assessing associations of COVID-19 diagnosis with incident diabetes in the full cohort and the group restricted to individuals hospitalized within 30 days after the index date. Analyses were adjusted for age, race/ ethnicity, BMI, tobacco use, and facility location. We used multiple imputation with 10 sets of imputations for analyses that included BMI due to 20% missing values for this variable. Given that the incidence of diabetes in this cohort was <5% overall, the relative odds is expected to be approximately equal to the relative risk. For ease of interpretation, we reported the latter estimate in describing our results.

Mean ± SD age of participants was 59.0 ± 17.1 years, and 14% percent were female (n 5 376,274). Five percent (n 5 126,710) had one or more positive respiratory swab for SARS-CoV-2 (Table 1) (Tables 2  and 3) . P values for sex * SARS-CoV-2 interaction terms were significant at a threshold of <0.1 for all participants (P interaction at 120 days and over all follow-up time both <0.001) and among hospitalized participants (P interaction at 120 days 5 0.072, over all follow-up time 5 0.089).

In men, among all participants, factors associated with higher risk of incident diabetes at either time point included older age (60-69, 70-79, and $80 years compared with the reference category of 50-59 years), Black (vs. non-Black) race, Latinx (vs. non-Latinx) ethnicity, BMI (30-34.9, 35-39.9, and $40 kg/m 2 compared with the reference category of 18.5-24.9 kg/m 2 ), and former or current tobacco use. Among hospitalized participants, additional factors associated with higher risk of incident diabetes at either time point included older age (60-69, 70-79, and $80 years compared with the reference category of 50-59 years) and higher BMI (35-39.9, and $40 kg/m 2 compared with the reference category of 18.5-24.9 kg/m 2 ). In women, among all participants, factors associated with higher risk of incident diabetes at either time point included BMI (25-29.9, 30-34.9, 35-39.9, and $40 kg/m 2 compared with the reference category of 18.5-24.9 kg/m 2 ) and current tobacco use. Among hospitalized participants, no additional factors were significantly associated with higher risk of incident diabetes at either time point.

In this large national cohort of veterans, the presence of a positive respiratory swab for SARS-CoV-2 was associated with a higher risk of diabetes at 120 days and over all study follow-up time, at an average of 237 days of follow-up, in the general VHA population and among individuals requiring hospitalization in the 30 days after enrollment. Associations were present in men but not women. To our knowledge, this is among the largest U.S.-based studies to examine associations of SARS-CoV-2 infection with incident diabetes; is the first study with rigorous exclusion of individuals with undiagnosed diabetes prior to infection on the basis of not only diagnostic codes but also laboratory testing and pharmacy information; and is the first study with examination of sex-specific associations. In addition, we assessed whether diagnostic surveillance bias might have accounted for this association, since patients recently diagnosed with COVID-19 are likely to have more medical encounters that might reveal presence of diabetes. We found that the higher risk of diabetes among individuals with a positive respiratory swab for SARS-CoV-2 persisted when we restricted our analyses to infected and uninfected patients who had recently been hospitalized, with hospitalization as a proxy for opportunities for diagnostic surveillance.

Other infections (e.g., Helicobacter pylori, Mycobacterium tuberculosis, and hepatitis C) have previously been implicated in the development of type 2 diabetes (13). Reports of increased hyperglycemia and ketoacidosis among individuals acutely ill with COVID-19 suggest that SARS-CoV-2 might play a causal role in new-onset postviral diabetes (14) . Mechanisms hypothesized to contribute to loss of b-cell function after COVID-19 include 1) direct b-cell injury, 2) "bystander" effects on b-cells due to infection of other cells in the islet, exocrine pancreas, or microvasculature; or 3) systemic effects on insulin resistance or the inflammatory milieu due to glucocorticoid treatment or SARS-CoV-2 infection itself (15) . At this writing, however, the primary mechanism remains unclear. Future studies quantifying insulin secretion and sensitivity after COVID-19 are urgently needed to clarify mechanisms and guide therapy.

Existing research has in general shown an association between COVID-19 infection and higher prevalence and incidence of type 2 diabetes but has many important limitations, including lack of adjustment for BMI or other measures of body composition and lack of use of glucose and pharmacy data to identify diabetes, leading to inclusion of undiagnosed cases at onset of infection and underascertainment of cases during follow-up. A meta-analysis (eight studies, n 5 3,711 COVID-19 patients, 492 cases of diabetes) reported a pooled prevalence of new or undiagnosed diabetes of 14.4% (95% CI 5.9-25.8) among hospitalized individuals (16) compared with 7.4% among hospitalized individuals in the current report; however, because Data are presented as mean ± SD for continuous variables and n (%) for categorical variables. P values for comparisons of participants who were SARS-CoV-2 positive with participants without a positive test for SARS-CoV-2 were all significant at P < 0.001. *All participants: n followed for diabetes until 120 days = 2,183,657 (n = 2,079,281 without a positive test for SARS-CoV-2 and n = 104,376 with a positive test). Hospitalized participants: n followed for diabetes until 120 days = 43,966 (n = 33,785 without a positive test for SARS-CoV-2 and n = 10,181 with a positive test).

the meta-analysis included estimates of both new-onset and previously undiagnosed diabetes, the estimates cannot be interpreted as incidence estimates, which might account for the differences seen. (6) . Risk of type 1 diabetes was not significantly increased. These HRs are similar in magnitude to the OR among hospitalized men in our study. In an analysis of individuals hospitalized with COVID-19 in England (n 5 47,780) and control subjects taken from the general population, the incidence rate ratio of new-onset type 1 or type 2 diabetes identified by diagnostic codes in comparisons of individuals with COVID-19 and control subjects was 1.5 (95% CI 1.4-1.6) (7)-very similar to previously reported estimates (6) and findings among men in the current report.

We also found that associations were present among men but not women. Female sex is associated with a lower risk of COVID-19 mortality (17) . Some authors have hypothesized that this may be due to sex differences in immune responses (18) . A similar phenomenon may underlie the results we found in the current analysis. This is an area deserving of future study with potential to inform novel prevention strategies.

Our study has several strengths, most importantly, the large, well-characterized national sample. We used ICD codes, laboratory values, and/or glucose-lowering medication use to define diabetes-a more sensitive approach than strategies that rely entirely on diagnostic codes (19) . analysis among the hospitalized to correct for diagnostic surveillance imbalance, there is still potential that surveillance bias may have occurred favoring detection of diabetes in the SARS-CoV-2-positive participants. We did not examine the role of prior glycemia below thresholds for diabetes diagnosis in the association of SARS-CoV-2 infection with incident diabetes, and we did not examine the role of systemic corticosteroid use in the pathogenesis of diabetes after SARS-CoV-2 infection or to what extent higher risk of diabetes was accounted for by this exposure. These are important areas deserving of future study. We did not ascertain admission diagnoses; however, cardiovascular disease is the leading cause of hospitalization in the VHA (21). Lastly, we did not identify SARS-CoV-2 infections that occurred outside VHA. This form of misclassification would tend to bias findings toward the null.

In conclusion, among veterans without prevalent diabetes, a COVID-19 diagnosis was associated with higher risk of incident diabetes even after increased surveillance related to hospitalization is accounted for. The magnitude of the association that we observed is greater than previous reports on this topic. Future research is needed to determine the clinical course of post-COVID-19 diabetes, assess pathophysiologic mechanisms, and optimize diabetes surveillance strategies among COVID-19 survivors. No other potential conflicts of interest relevant to this article were reported. Author Contributions. P.L.W. conceived the project, designed the overall research plan, and wrote the first draft of the manuscript. E.L. analyzed data and reviewed and edited the manuscript. L.A.B. reviewed and edited the manuscript. L.T.-P. reviewed and edited the manuscript. A.K. contributed to the design and interpretation of the analyses and reviewed and edited the manuscript. A.C.P. contributed to the design and interpretation of the analyses and reviewed and edited the manuscript. S.E.K. contributed to interpretation of the analyses and reviewed and edited the manuscript. E.J.B. conceived the project, designed the overall research plan, and reviewed and edited the manuscript. P.L.W. and E.J.B. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

) 593 (6) Tobacco use Never 986

Accessed 24

Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence

Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study

High-dimensional characterization of post-acute sequelae of COVID-19

Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study

Newonset diabetes in Covid-19

American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes-2020

Robust causal inference using directed acyclic graphs: the R package 'dagitty'

Infections: a possible risk factor for type 2 diabetes

Diabetic ketoacidosis in patients with COVID-19

Not so sweet and simple: impacts of SARS-CoV-2 on the b cell

Proportion of newly diagnosed diabetes in COVID-19 patients: A systematic review and meta-analysis

Sex differences in severity and mortality from COVID-19: are males more vulnerable?

Understanding immune effects of oestrogens to explain the reduced morbidity and mortality in female versus male COVID-19 patients. Comparisons with autoimmunity and vaccination

Systematic review of validated case definitions for diabetes in ICD-9-coded and ICD-10-coded data in adult populations

Health disparities in veterans: a map of the evidence

Acknowledgments. The authors gratefully acknowledge the support of VA Puget Sound Health Care System. Funding. This study was funded by VA Office of Research and Development (COVID19-8990-19). The study sponsor/funder was not involved in the design of the study; the collection, analysis, or interpretation of data; or writing the manuscript and did not impose any restrictions regarding the publication of the manuscript. Duality of Interest. S.E.K. has served as a consultant and on advisory boards for Bayer, Boehringer Ingelheim, Casma Therapeutics, Eli Lilly and Co., Intarcia, Merck, Novo Nordisk,